| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| ln Vitro |
The vitality of colon cancer cell lines with different pathological and genetic characteristics (e.g., SW480, HCT116, SW620, and LoVo cells) is dose-dependently inhibited by lidocaine (LCD) (0–20 μM; 24 hours), with IC50 values of 7.2, 5.4, 4.5 are 5.1 μM and 5.1 μM, respectively [1]. Apoptosis is induced by lidocaine (LCD) (0–20 μM; 0–12 h), and in a dose- and time-dependent manner, this is followed by the cleaved activation of caspase-3 [1]. Licoricidin (LCD) (0-20 μM; 0-12 hours) stimulates autophagy in SW480 cells, leading to a time- and dose-dependent increase in p62 degradation and LC3-I to LC3-II cleavage [1]. In 4T1 cells, lidocidin (LCD) (0–5 μg/ml; 18 hours) decreases MMP-9 production, VCAM expression, and cell migration [2].
|
|---|---|
| ln Vivo |
The growth of SW480 xenografts in nude mice was considerably decreased by lidocaine (LCD) (intraperitoneal injection; 5, 10 or 20 mg/kg; once daily; 15 days) with an inhibition rate of 43.5% [1]. Moreover, the protein expression of VEGF-R2, VEGF-C, VEGF-R3, and LYVE-1 in tumor tissues of mice treated with liquiritin decreased [2]. Liquiritin (LCD) (ip; 5, 10, or 20 mg/kg; once daily; 32 days) lowers lung metastasis and expression of CD45, CD31, HIF-1α, iNOS, COX-2, and VEGF-A.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: SW480, HCT116, SW620 and LoVo Cell Tested Concentrations: 0-20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Colon cancer cell line viability diminished. Western Blot Analysis [1] Cell Types: SW480 cell Tested Concentrations: 0 μM, 2.5 μM, 5 μM, 10 μM, 20 μM Incubation Duration: 0 hrs (hours), 1 hour, 3 hrs (hours), 6 hrs (hours), 12 hrs (hours) Experimental Results: Induction of apoptosis . |
| Animal Protocol |
Animal/Disease Models: SW480 nude mouse xenograft tumor growth [1]
Doses: 5, 10 or 20 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day; 15-day Experimental Results: tumor volume reduction. Animal/Disease Models: BALB/c mouse orthotopic model [2] Doses: 5, 10 or 20 mg/kg Route of Administration: intraperitoneal (ip) injection; 5, 10 or 20 mg/kg; one time/day; 32-day Experimental Results: Inhibition of 4T1 mice Lung metastasis of breast cancer cells. |
| References |
|
| Additional Infomation |
Licoricidin is a member of the class of hydroxyisoflavans that is R-isoflavan with hydroxy groups at positions 7, 2' and 4', a methoxy group at position 5 and prenyl groups at positions 6 and 3'. Isolated from Glycyrrhiza uralensis, it exhibits antibacterial activity. It has a role as an antibacterial agent and a plant metabolite. It is a member of hydroxyisoflavans, an aromatic ether and a methoxyisoflavan.
Licoricidin has been reported in Glycyrrhiza uralensis, Glycyrrhiza aspera, and other organisms with data available. See also: Glycyrrhiza uralensis Root (part of). |
| Molecular Formula |
C26H32O5
|
|---|---|
| Molecular Weight |
424.5293
|
| Exact Mass |
424.224
|
| CAS # |
30508-27-1
|
| PubChem CID |
480865
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
610.8±55.0 °C at 760 mmHg
|
| Melting Point |
161.0-162.5℃
|
| Flash Point |
323.2±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| LogP |
6.36
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
636
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2C([H])=C(C(C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])=C(C=2C([H])([H])[C@]([H])(C2C([H])=C([H])C(=C(C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])C=2O[H])O[H])C1([H])[H])OC([H])([H])[H])O[H]
|
| InChi Key |
GBRZTUJCDFSIHM-KRWDZBQOSA-N
|
| InChi Code |
InChI=1S/C26H32O5/c1-15(2)6-8-19-22(27)11-10-18(25(19)29)17-12-21-24(31-14-17)13-23(28)20(26(21)30-5)9-7-16(3)4/h6-7,10-11,13,17,27-29H,8-9,12,14H2,1-5H3/t17-/m0/s1
|
| Chemical Name |
4-[(3R)-7-hydroxy-5-methoxy-6-(3-methylbut-2-enyl)-3,4-dihydro-2H-chromen-3-yl]-2-(3-methylbut-2-enyl)benzene-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~235.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3555 mL | 11.7777 mL | 23.5555 mL | |
| 5 mM | 0.4711 mL | 2.3555 mL | 4.7111 mL | |
| 10 mM | 0.2356 mL | 1.1778 mL | 2.3555 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
